Table 1.

Current ASCO recommendations on gene profile assays in HR+/HER2- early breast cancer. Adapted from Andre et al. [11]. BCI, Breast Cancer Index; evidence quality: high (++), intermediate (+); strength of recommendation: strong (++), moderate (+); insufficient evidence to recommend a biomarker (−).

Lymph Node Status	Premenopausal or Age ≤ 50 Years (Evidence Quality/Strength of Recommendation)	Postmenopausal or Age > 50 Years (Evidence Quality/Strength of Recommendation)
Node-negative	Oncotype Dx (++/++)	Oncotype Dx (++/++) MammaPrint (+/++) EndoPredict® (+/+) Prosigna (+/+) BCI (+/+)
1–3 positive nodes	(−)	Oncotype Dx (++/++) MammaPrint (+/++) EndoPredict® (+/+) BCI (+/+)
≥4 positive nodes	Insufficient evidence to recommend a biomarker